We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Symptoms and Endoscopic Results in Consideration of Pretreatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00612404
First Posted: February 11, 2008
Last Update Posted: February 11, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. gastroenterologists) are asked to document relevant data in patients with gastrointestinal disorders.

Condition
Gastrointestinal Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Symptoms and Endoscopic Results in Consideration of Pretreatment

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • to gain insight into the relationship between subjective gastrointestinal symptoms and findings of a laryngopharyngeal-esophagogastric endoscopy with respect to the medicinal pre-therapy;

Secondary Outcome Measures:
  • to gain insight into the currently used treatment strategies with esomeprazole depending on endoscopic findings.

Enrollment: 16255
Study Start Date: September 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
patients with gastrointestinal disorders who need an endoscopy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
gastroenterologists; specialists
Criteria

Inclusion Criteria:

  • patients with gastrointestinal disorders who need an endoscopy.

Exclusion Criteria:

  • limitiations; possible risks; warnings; contraindications mentioned in the SPC.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00612404


Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Kai Richter, MD Medical Department AstraZeneca Germany
  More Information

Responsible Party: Dr Kai Richter, AstraZeneca Germany
ClinicalTrials.gov Identifier: NCT00612404     History of Changes
Other Study ID Numbers: 1312004008
First Submitted: January 28, 2008
First Posted: February 11, 2008
Last Update Posted: February 11, 2008
Last Verified: January 2008

Keywords provided by AstraZeneca:
gastrointestinal disorder
endoscopy
patient with gastrointestinal disorders for whom an endoscopy is performed and who is treated with esomeprazole afterwards.

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases